Sugi Predict

Sugi Predict / Compounds / SCHEMBL24719366

SCHEMBL24719366

SCHEMBL24719366

CNC(=O)Nc1ccc(-c2cccc(-c3cc(N4CCNCC4)no3)c2O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 4/20 0.43
▸ KDR P35968 6/20 0.39
▸ FLT3 P36888 5/20 0.39
▸ AURKA O14965 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MTOR P42345 5/20 0.39
▸ PIK3CA P42336 4/20 0.39
▸ PIK3CG P48736 2/20 0.39
▸ CHEK1 O14757 1/20 0.36
▸ KIT P10721 4/20 0.36
▸ CSF1R P07333 2/20 0.36
▸ LCK P06239 2/20 0.36
▸ SRC P12931 2/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ FYN P06241 1/20 0.36
▸ LYN P07948 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30124375 1.00 MAPKAPK2 (0.43) MAPKAPK2KDRFLT3AURKAKDM4E
SCHEMBL24719664 0.90 MAPKAPK2 (0.45) MAPKAPK2KDRFLT3AURKAMAPT
SCHEMBL30124692 0.90 MAPKAPK2 (0.45) MAPKAPK2KDRFLT3AURKAMAPT
Bromide SCHEMBL29182796 0.90 MAPKAPK2 (0.44) MAPKAPK2KDRFLT3AURKAMAPT
SCHEMBL24951667 0.89 MAPKAPK2 (0.43) MAPKAPK2KDRFLT3AURKAKDM4E
SCHEMBL24720315 0.88 AURKA (0.45) MAPKAPK2KDRFLT3AURKAKDM4E
SCHEMBL24720278 0.86 MAPKAPK2 (0.43) MAPKAPK2KDRFLT3AURKAMTOR
SCHEMBL24951689 0.86 MAPKAPK2 (0.43) MAPKAPK2KDRFLT3AURKACHEK1
SCHEMBL24952054 0.86 MAPKAPK2 (0.43) MAPKAPK2KDRFLT3AURKAMTOR
Trifluoroacetic Acid SCHEMBL30146760 0.84 MAPKAPK2 (0.41) MAPKAPK2CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. 2024-07-04 — — US disclosed
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. 2024-07-04 — — US disclosed
WO-2024123999-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN POSEIDON INNOVATION 1, INC. (US) 2024-06-13 — — WO disclosed
CN-117794525-A Anticancer compounds 加利福尼亚大学董事会 2024-03-29 — — CN disclosed
US-20230025178-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-01-26 — — US disclosed
WO-2022261204-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025178-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA MAPKAPK2 2219/4885KDR 3544/4885FLT3 1536/4885
US-20240217952-A1 TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN BRDT, BET1, BRD4 MAPKAPK2 3146/4885KDR 4225/4885FLT3 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.